Applied Therapeutics, Inc. (APLT)
NASDAQ: APLT · IEX Real-Time Price · USD
4.350
-0.260 (-5.64%)
At close: Jul 2, 2024, 4:00 PM
4.270
-0.080 (-1.84%)
After-hours: Jul 2, 2024, 7:24 PM EDT
Applied Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for APLT stock have an average target of 11, with a low estimate of 7.00 and a high estimate of 13. The average target predicts an increase of 152.87% from the current stock price of 4.35.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 11, 2024.
Analyst Ratings
The average analyst rating for APLT stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 1 | 2 | 3 | 3 | 3 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $12 | Buy | Reiterates | $12 | +175.86% | Apr 11, 2024 |
| RBC Capital | RBC Capital | Buy Initiates $12 | Buy | Initiates | $12 | +175.86% | Mar 26, 2024 |
| UBS | UBS | Strong Buy Maintains $12 → $13 | Strong Buy | Maintains | $12 → $13 | +198.85% | Mar 15, 2024 |
| UBS | UBS | Strong Buy Maintains $4 → $12 | Strong Buy | Maintains | $4 → $12 | +175.86% | Mar 6, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $12 | Buy | Initiates | $12 | +175.86% | Feb 22, 2024 |
Financial Forecast
Revenue This Year
4.51M
from 9.99M
Decreased by -54.84%
Revenue Next Year
60.11M
from 4.51M
Increased by 1,231.89%
EPS This Year
-1.19
from -1.42
EPS Next Year
-0.47
from -1.19
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 10.7M | 117.6M | 201.1M | 290.6M | 408.2M |
| Avg | 4.5M | 60.1M | 121.6M | 282.3M | 396.6M |
| Low | 1.9M | 11.6M | 50.1M | 271.2M | 381.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 7.2% | 2,506.0% | 234.6% | 139.0% | 44.6% |
| Avg | -54.8% | 1,231.9% | 102.3% | 132.1% | 40.5% |
| Low | -80.9% | 157.1% | -16.7% | 123.0% | 35.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.77 | -0.25 | 0.31 | 0.56 | 1.12 |
| Avg | -1.19 | -0.47 | 0.06 | 0.54 | 1.09 |
| Low | -1.62 | -0.61 | -0.14 | 0.52 | 1.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 780.0% | 107.8% |
| Avg | - | - | - | 754.8% | 101.9% |
| Low | - | - | - | 721.3% | 94.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.